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respectively 24 months since occurrence of cranial disease manifesta-
tion in line with a considerable quality of life improvement asks to 
investigate more systematically the best use of targeted therapies after 
whole brain irradiation.
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Purpose: EGFR mutations deﬁne a subset of NSCLC with sensitivity 
to geﬁtinib or erlotinib. However, all EGFR mutations are not equal 
and may have different predictive and prognostic value. In this study 
we compared classical “hot spot” and “rare” EGFR mutations in terms 
of response to 1st line chemotherapy and overall survival in a cohort of 
patients with advanced NSCLC.
Patients and Methods: Tumor samples were formalin ﬁxed parafﬁn-
embedded tissues that were microdissected to achieve purity 80% in 
cancer cells. EGFR mutations were analyzed by DNA sequencing of 
exons 18 to 21 in both forward and reverse directions in PCR products 
from tumor genomic DNA. 
Results: Of the 169 patients assessable for mutation detection we 
found 12 (7%) positive for classical “hot spot” (G719D, Del 19, 
E746V, L747S, L858R) EGFR mutations and 34 (20%) positive for 
“rare” EGFR mutations. Classical but not rare mutations were associ-
ated with female gender and never smoking history (P=0.002; P<0.001 
and P=0.637; P=0.402, respectively). However, the histological type 
had no signiﬁcant association with either type of EGFR mutations 
(P=0.520 and P=0.260, respectively).
Response rates to ﬁrst-line chemotherapy were signiﬁcantly higher 
in patients bearing classical mutations (60%) but not in those with 
rare EGFR mutations (29%) as compared with patients with wild-
type EGFR (20.4%) (p=0.005 and p=0.311, respectively). Time to 
tumor progression was 65 weeks, 22 weeks and 33 weeks for patients 
with classical mutations, rare EGFR mutations and wild type EGFR, 
respectively (p=0.165 and p=0.327 as compared to wild type). Overall 
survival was longer in patients bearing classical mutations (p=0.006) 
but not in those with rare mutations (p=0.843) as compared to patients 
with wild type EGFR.
Conclusions: Different EGFR mutation patterns are associated with 
higher response to ﬁrst-line chemotherapy and longer overall survival 
in patients with advanced NSCLC. 
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Background: EGFR mutations in non-small-cell lung cancer (NSCLC) 
are associated with sensitivity to geﬁtinib and erlotinib. However, the 
correlation of EGFR mutation status between primary tumor and me-
tastases is not established. To investigate this, we analyzed 18 patients 
with paired samples of primary and metastatic NSCLC.
Methods: Tumor metastases include adrenal gland, liver, bone, brain, 
lung, skin and thoracic wall. All tumor samples were formalin ﬁxed 
parafﬁn-embedded tissues. Exons 18, 19, 20 and 21 of the EGFR were 
ampliﬁed by PCR and the products were directly sequenced on an ABI 
3100 Avant genetic analyzer. All mutations were conﬁrmed by sequenc-
ing in both directions and by an independent PCR ampliﬁcation.
Results: In 12 cases there was concordance between the primary tumor 
and the corresponding metastases, with EGFR status determined as 
wild type. Discordance was observed in six cases (33.3%): in three 
cases EGFR was mutated only in the primary tumor, while in two cases 
EGFR mutations were found only in metastases. Finally, in one patient 
the metastases had an additional mutation besides that of the primary 
tumor. Two out of 18 patients carried the L692P-V717A and T847A 
mutations respectively only in their metastases. The time to tumor 
progression (TTP) in 1st line chemotherapy was 29 weeks for the 
patient carrying the double mutation (L692P-V717A) and 307 weeks 
for the patient carrying the T847A mutation. Seven out of 18 patients 
were treated with geﬁtinib. Three of them had no mutations in both 
the primary and metastatic tumors and the median TTP was 20 weeks. 
Three patients carried the E746V, L692P and G857E mutations, respec-
tively, in their primary tumors but were wild type in their metastases. 
Interestingly, these patients received RTK inhibitors prior to develop-
ing the metastases. The median TTP for them was 59 weeks. The last 
patient who carried the Del 19 in his primary tumor and the Del 19 and 
T790M in his metastases received geﬁtinib before the second surgery 
and exhibited TTP of 80 weeks.
Conclusions: Our ﬁndings suggest a discordance of EGFR mutation 
status between primary tumor and metastases and imply a possible role 
for EGFR mutation analysis of metastases for the treatment of meta-
static NSCLC with RTKIs.
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Background: Geﬁtinib is an effective treatment for chemotherapy-
resistant East Asian NSCLC patients. The efﬁcacy of geﬁtinib in che-
monaive NSCLC patients bearing different types of EGFR mutations in 
their tumor tissue and who are candidates for standard chemotherapy is 
unclear. It is important to know the precise response rates and response 
durations of geﬁtinib in these patients in order to compare this novel 
approach with standard chemotherapy. 
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Methods: A phase II study was designed to collect geﬁtinib anti-tumor 
efﬁcacy information of advanced stage NSCLC patients. Eligibility 
criteria included histological or cytological proven chemonaive stage 
IIIB/IV NSCLC, measurable disease, ECOG performance status of 0-2, 
good organ functions and candidates for platinum-based chemotherapy. 
Patients were treated with 250mg geﬁtinib per day. Tumor assessments 
were performed every two months by RECIST criteria. Responding 
or stable patients were treated until progression. To avoid bias in the 
objective response assessment, tumor samples were collected and 
tested for EGFR mutation when most patients were progressed on the 
treatment. Therefore, investigators were blinded to the tumor EGFR 
mutational status results when tumor responses were assessed. A 
radiologist independently reviewed all scans of the responding patients. 
Simon’s two-stage design was used to aim at a response rate more than 
20%. A total of 106 patients were planned. 
Results: There were 38 men and 68 women. Median age was 66.7 
(range 32.3-86.2). ECOG performance status of 0/1/2 were 0/98/8. 
There were 75 /19 / 12 patients who were nonsmokers / quitted for 1 
year / current smokers. Ninety-seven (91.5%) patients had adenocar-
cinoma histology. Investigator-assessed tumor responses are presented 
here. There were 1/58/29/14/4 patients with CR/PR/SD/PD/NE. Over-
all response rate was 55.7% (95% conﬁdence interval 46.2-65.2%) and 
disease control rate was 81.1%. EGFR gene mutation analyses were 
performed in 83 patients’ tumor samples using polymerase chain reac-
tion ampliﬁcation and direct DNA sequencing. Mutations of exons 18, 
19, 20, 21(L858R), 21(other mutations) were detected in 1/19/6/19/6 
patients. The response rate and duration of 19 patients with del 19 were 
94.7% and 11.8 months. The response rate and duration of 19 patients 
with L858R mutation were 84.2% and 11.5 months. The response prob-
abilities in patients with other mutations were low. The response rate 
for 32 patients with wild type EGFR was 28.1%. The response rate was 
65.2% in 23 patients whose EGFR mutation test were not performed. 
The response rates and durations of patients with different types of 
EGFR mutations using independent review results will be presented in 
the meeting.
Conclusions: Consistent high response rates and long response dura-
tions were observed in chemonaive good performance advanced stage 
NSCLC patients with deletion 19 or L858R mutations of EGFR in their 
tumor samples. In a good-predictive -factor enriched population, the 
response rate were still higher than or comparable to patients receiving 
chemotherapy if EGFR was tested wild type in their tumor samples or 
if mutation test can not be performed. 
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Background and Objective: Recent studies showed that somatic 
mutations in epidermal growth factor receptor(EGFR) tyrosine 
kinase(TK) domain are associated with sensitivity of non-small cell 
lung cancer(NSCLC) to TK inhibitor. This study was to analyze 
EGFR mutations in patients with NSCLC. Method: Specimens of lung 
cancer were collected from 90 consecutive NSCLC patients DNA was 
extracted from the 90 specimens.Exons19 and 21 were ampliﬁed by 
polymerase chain reaction (PCR), and sequenced and analyzed from 
both sense and antisense directions. 
Result: Somatic mutations in TK domain of EGFR in tumors were 
identiﬁed from 26 of the 90(28.9%)patients, including 16 cases(64.0%) 
of in-frame deletion in exon 19 and 9 cases(36.0%) of amino acid 
substitution in exon 21. Mutation rate was signiﬁcantly higher in 
adenocarcinoma and bronchioalveolar carcinoma than in squamous cell 
carcinoma[13/35(37.1%),and 90.0%(9/10) vs. 4/45(8.9%),P<0.0001],: 
and signiﬁcantly higher in non-smokers than in smokers[18/36(50%) 
vs 8/54(14.8%),P=0.001].: Mutation rate in women was also higher 
than in men [15/25(60%) vs 11/65(16.9%),P<0.0001]: Mutations rate 
in patients with advanced lung cancer(III, IV stage) are higher than that 
in early stage(I, II stage)[15/71(21.1%) vs 11/19(57.9%),P=0.004]: But 
there is no signiﬁcant difference in the patients of different age(<70y or 
.≥70y) [ 17/62(27.4%) vs 9/28(32.1%), P=0.534].
Conclusion: EGFR mutation rate in Chinese NSCLC patients is high. 
Adenocarcinoma (bronchioalveolar carcinoma in particularly ), non-
smoker, femal patients and patients with advanced lung cancer are four 
important factors to predict EGFR mutation.
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Gene mutations in the ATP binding site of EGFR is a well-known 
predictive factor for chemosensitivity of geﬁtinib. However, several 
additional predictive factors for geﬁtinib sensitivity were reported, i.e., 
EGFR copy number, k-ras mutation, and the other erbB family mol-
ecules. To investigate all of these predictive factors is too expensive. 
Therefore, we are now trying to evaluate chemosensitivity for geﬁtinib 
in non-small cell lung cancer, using an in vitro drug sensitivity test.
Materials and Methods: Surgically resected fresh tumor specimens 
obtained from the 22 patients with non-small cell lung cancer were 
used. There were 13 males, 9 females, ranging in age 49-84 (average 
70) years old. Sixteen patients (73%) were smokers. Sixteen adenocar-
cinoma, 4 squamous cell carcinoma, 1 lymphoepithelioma-like carci-
noma, and 1carcinoid were included. Histoculture drug response assay 
(HDRA) were used as an in vitro drug sensitivity test. HDRA technique 
was the same as we previously reported (JTCVS 133: 303-8, 2007). 
Small pieces of viable cancer tissue was placed on the collagen gel, and 
then cultured 7 days in the presence of the geﬁtinib. Concentrations of 
geﬁtinib were 5, 10, 20, and 40 μg/ml. MTT assay was used to evaluate 
the viability of cancer tissue after incubation. The inhibition rate was 
calculated by using the following formula.
Inhibition rate (%) = (1 - mean absorbance of treated tumor/weight / 
mean absorbance of control tumor /weight) x 100.
Results: Assay was successful in all specimens. Average inhibition 
rates at the concentration of 5, 10, 20, and 40 μg/ml were 8.4%, 9.8%, 
16.9%, and 45.8%, respectively. Dose-response relationship was 
observed between the inhibition rates and the geﬁtinib concentrations 
(p=0.02). In 4 patients, the inhibition rate was evaluated only at the 
concentration of 20 μg/ml (I20). 
